5 July 2018

Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.

Viken, May 28th, 2018

TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company has been granted permission for a clinical trial (Phase 2a) in ALS (Amyotrophic Lateral Sclerosis) at Sahlgrenska University Hospital by the Swedish Medical Product Agency and Ethical Review Board.

Anders Svenson M.D., Chief Medical Officer of TikoMed, commented, “Today, we present an important milestone, with the granted permission by the Swedish Medical Product Agency and Ethical Review Board for our first phase 2a clinical trial, and we look forward to start initiating the ALS clinical trial in the coming months at Sahlgrenska Univeristy Hospital. We believe the ILB technology has significant potential for ALS and we therefore look forward to the study outcome later this year.”

The study will be performed at and in collaboration with Sahlgrenska University Hospital, Gothenburg, Sweden. Assoc. Professor Lennart Persson, a world renowned key opinion leader, will be principal investigator.15 patients will be treated with ILB during a 4-week period.

Tikomed is also preparing for an ALS study with Birmingham University Hospital, UK. 15 patients will be treated with ILB during a 10-week period.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

5 July 2018
ILB – A game changer in Glaucoma
Viken, May 22nd, 2018 TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for…
Read More
5 June 2018
Anders Kristensson appointed CEO of TikoMed
Viken – 18th June 2018 TikoMed, a privately-held biopharmaceutical company today announced the appointment of…
Read More
27 April 2018
TIKOMED IS INTERVIEWED BY RAPIDUS
TikoMed fyller kassan inför ALS-studier 2018-04-23 Läkemedelsbolaget TikoMed från skånska Viken fyller på kassan med…
Read More
SEE MORE